
Emtricitabine
CAS No. 143491-57-0
Emtricitabine( BW-1592 )
Catalog No. M11849 CAS No. 143491-57-0
A nucleoside reverse transcriptase inhibitor (NRTI) for the prevention and treatment of HIV infection.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
50MG | 41 | In Stock |
![]() ![]() |
100MG | 61 | In Stock |
![]() ![]() |
500MG | 102 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameEmtricitabine
-
NoteResearch use only, not for human use.
-
Brief DescriptionA nucleoside reverse transcriptase inhibitor (NRTI) for the prevention and treatment of HIV infection.
-
DescriptionA nucleoside reverse transcriptase inhibitor (NRTI) for the prevention and treatment of HIV infection; also exhibits clinical activity against the hepatitis B virus (HBV).HIV Infection Approved(In Vitro):Emtricitabine has in vitro activity against both laboratory strains of HIV-1 and HIV-2 and clinical isolates of HIV-1. The 50% effective concentration (EC50) ranges from 0.002 to 1.5 μ mol/L, depending on the viral isolate and cell line used. Emtricitabine demonstrates in vitro synergy with zidovudine and stavudine and additive in vitro activity when combines with zalcitabine or didanosine.(In Vivo):Reproductive and developmental toxicology studies are conducted with emtricitabine. Oral doses up to 1000 mg/kg/day provided daily area under the curve (AUC0→24) exposure to pregnant animals approximately 60- (mice) to 120-fold (rabbits) higher than that in humans at the recommended dose of 200 mg given once per day. In a mouse fertility study, emtricitabine had no effect on fertility, sperm count, or early embryonic development. There is no increased incidence of malformations in mouse and rabbit embryofetal toxicology studies. The development and fertility of F1 progeny are unaffected by emtricitabine in a mouse pre- and post-natal study. These data demonstrate a favorable pre-clinical reproductive safety profile for emtricitabine.
-
In Vitro——
-
In Vivo——
-
SynonymsBW-1592
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorReverseTranscriptase
-
Research AreaInfection
-
IndicationHIV Infection
Chemical Information
-
CAS Number143491-57-0
-
Formula Weight247.2467
-
Molecular FormulaC8H10FN3O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10.8 mg/mL
-
SMILESC1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F
-
Chemical Name2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Saag MS. Clin Infect Dis. 2006 Jan 1;42(1):126-31.
2. Darque A, et al. Antimicrob Agents Chemother. 1999 Sep;43(9):2245-50.
3. Rousseau FS, et al. J Infect Dis. 2003 Dec 1;188(11):1652-8.
molnova catalog



related products
-
Doravirine
Doravirine (MK-1439, MK1439) is a novel, highly specific HIV-1 nonnucleoside reverse transcriptase inhibitor (NNRTI) with IC50 of 12, 9.7, and 9.7 nM against WT, K103N, and Y181C reverse transcriptase (RT) mutants, respectively.
-
HIV-1 Rev 34-50
HIV-1 Rev (34-50) is a 17-aa peptide derived from the Rev-responsive element (RRE)-binding domains of Rev in HIV-1, with anti-HIV-1 activity. HIV-1 Rev peptide is a one of the cell-penetrating peptides (CPPs) derived from HIV-1 Rev protein residue 34-50. It is a RNA binding peptideand has been used to deliver macromolecules into cells.
-
Ritonavir
A potent HIV protease inhibitor for treatment of HIV-1 infection.